Article
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Blood - 1 Sept 2016
Kortüm K Martin, Mai Elias K, Hanafiah Nur H, Shi Chang-Xi, Zhu Yuan-Xiao, Bruins Laura, Barrio Santiago, Jedlowski Patrick, Merz Maximilian, Xu Jing, Stewart Robert A, Andrulis Mindaugas, Jauch Anna, Hillengass Jens, Goldschmidt Hartmut, Bergsagel P Leif, Braggio Esteban, Stewart A Keith, Raab Marc S
Abstract excerpt
In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation Panel. Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), and 88%, 78%, and 68% were refractory to an IMiD, a PI, or both, respectively. The majority of patients had progressive (82%) or refractory (78%) disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.